Načítá se...
Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection
CONTEXT: Traditional hepatitis C virus treatment was limited by low cure rates, side effects, and stringent monitoring requirements. Sofosbuvir, a direct-acting antiviral agent with a cure rate of 96%, was introduced in 2013. However, trials frequently excluded patients with advanced liver disease a...
Uloženo v:
| Vydáno v: | Perm J |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
The Permanente Journal
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5378486/ https://ncbi.nlm.nih.gov/pubmed/28368787 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7812/TPP/16-096 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|